RLAY.US Relay Therapeutics Inc

Healthcare Biotechnology USA Stocks
16.47 USD
Close of Nov 18, 2026
6.28 21.27
Market cap
USD 3.64B
P/E
-
P/B
4.66x
ROE
-38.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RLAY.US undervalued?

Graham number

The Graham number of Relay Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Relay Therapeutics Inc fundamental analysis

No fundamental analysis for Relay Therapeutics Inc yet.

Relay Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular m…

Full company profile